Tuhura Biosciences Inc. logo

Tuhura Biosciences Inc. (KTRA)

Market Closed
17 Oct, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 22
-0.01
-6.31%
$
11.99M Market Cap
- P/E Ratio
0% Div Yield
3,552,720 Volume
-1.05 Eps
$ 0.23
Previous Close
Day Range
0.2 0.24
Year Range
0.2 26.21
Want to track KTRA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

KTRA closed Thursday lower at $0.22, a decrease of 6.31% from Wednesday's close, completing a monthly increase of 0% or $0.22. Over the past 12 months, KTRA stock gained 0%.
KTRA is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Tuhura Biosciences Inc. has completed 4 stock splits, with the recent split occurring on Oct 18, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

KTRA Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Tuhura Biosciences Inc. Dividends

KTRA is not paying dividends to its shareholders.

Tuhura Biosciences Inc. Earnings

12 May 2025 Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Oct 2024 Date
-
Cons. EPS
-
EPS
7 Oct 2024 Date
-
Cons. EPS
-
EPS
KTRA is not paying dividends to its shareholders.
12 May 2025 Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
-
Cons. EPS
-
EPS
11 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Oct 2024 Date
-
Cons. EPS
-
EPS
7 Oct 2024 Date
-
Cons. EPS
-
EPS

Tuhura Biosciences Inc. (KTRA) FAQ

What is the stock price today?

The current price is $0.22.

On which exchange is it traded?

Tuhura Biosciences Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is KTRA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 11.99M.

Has Tuhura Biosciences Inc. ever had a stock split?

Tuhura Biosciences Inc. had 4 splits and the recent split was on Oct 18, 2024.

Tuhura Biosciences Inc. Profile

Biotechnology Industry
Healthcare Sector
Jeffrey A. Bacha CEO
NASDAQ (CM) Exchange
49720K101 Cusip
US Country
1 Employees
- Last Dividend
18 Oct 2024 Last Split
22 Feb 2013 IPO Date

Overview

Kintara Therapeutics, Inc. is a clinical stage drug development company focused on the creation and commercialization of novel anti-cancer therapies. The company is at the forefront of developing two Phase III-ready therapeutics, targeting a range of difficult-to-treat solid tumors and other cancer-related conditions. Originally founded in 2009 as DelMar Pharmaceuticals, Inc., the company underwent a rebranding to Kintara Therapeutics, Inc. in August 2020. Its mission is to address the unmet medical needs of cancer patients, particularly those battling drug-resistant cancers. Headquartered in San Diego, California, Kintara has formed a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., enabling the manufacture and sale of its leading compound VAL-083 in China.

Products and Services

Kintara Therapeutics, Inc. is dedicated to advancing a portfolio of promising anti-cancer treatments. These include:

  • VAL-083: This DNA-targeting agent is designed for the treatment of drug-resistant solid tumors, with a focus on glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. VAL-083 represents a new hope for patients with these aggressive cancers, offering a potential treatment option where current therapies have failed. Kintara is positioning VAL-083 as a key player in the oncology field, underscoring its efficacy in overcoming resistance to conventional chemotherapies.
  • REM-001: In the later stages of development, REM-001 is a photodynamic therapy aimed at treating cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Photodynamic therapy, a minimally invasive treatment method that uses light-sensitive drugs and a light source to destroy cancer cells, provides a targeted approach to cancer treatment, minimizing damage to normal tissues. REM-001’s diverse applications highlight Kintara’s commitment to exploring innovative treatment avenues beyond traditional chemotherapy and radiation.

Contact Information

Address: 12707 High Bluff Drive
Phone: 858 350 4364